When MIA-602 was administered subcutaneously to the rats, impaired GLP-1 levels were restored, and dyslipidemia and hyperglucagonemia were blunted [121] suggesting that antagonizing GHRH signalling in type 1 diabetes may improve GLP-1 function in the intestine. This evidence concerns the gene GHRH and metabolic syndrome.